Literature DB >> 20926711

Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Johannes Schweizer1, Peter S Lu, Charles W Mahoney, Marthe Berard-Bergery, Minh Ho, Valli Ramasamy, Jon E Silver, Arnima Bisht, Yassine Labiad, Roger B Peck, Jeanette Lim, Jose Jeronimo, Roslyn Howard, Patti E Gravitt, Philip E Castle.   

Abstract

In a feasibility study using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45) E6 oncoproteins, 51 of 75 (68%; 95% confidence interval [95% CI] of 56 to 78%) of HPV16/18/45 DNA-positive specimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) tested positive for HPV16/18/45 E6 oncoprotein. None of 16 (95% CI of 0 to 37%) HPV16/18/45 DNA-positive cervical specimens from women with a negative or CIN1 diagnosis tested positive for HPV16/18/45 E6 oncoprotein.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20926711      PMCID： PMC3008434          DOI： 10.1128/JCM.01315-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  A review of human carcinogens--Part B: biological agents.

Authors:  Véronique Bouvard; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Vincent Cogliano
Journal:  Lancet Oncol       Date:  2009-04       Impact factor: 41.316

3.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

Authors:  You-Lin Qiao; John W Sellors; Paul S Eder; Yan-Ping Bao; Jeanette M Lim; Fang-Hui Zhao; Bernhard Weigl; Wen-Hua Zhang; Roger B Peck; Ling Li; Feng Chen; Qing-Jing Pan; Attila T Lorincz
Journal:  Lancet Oncol       Date:  2008-09-19       Impact factor: 41.316

4.  Heterogeneity in CIN3 diagnosis.

Authors:  Mark Schiffman; Ana Cecilia Rodríguez
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

5.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

6.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

7.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

Authors:  Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

8.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

9.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

10.  HPV screening for cervical cancer in rural India.

Authors:  Rengaswamy Sankaranarayanan; Bhagwan M Nene; Surendra S Shastri; Kasturi Jayant; Richard Muwonge; Atul M Budukh; Sanjay Hingmire; Sylla G Malvi; Ranjit Thorat; Ashok Kothari; Roshan Chinoy; Rohini Kelkar; Shubhada Kane; Sangeetha Desai; Vijay R Keskar; Raghevendra Rajeshwarkar; Nandkumar Panse; Ketayun A Dinshaw
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245
  10 in total
  22 in total

Review 1.  Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Authors:  Vikrant V Sahasrabuddhe; Patricia Luhn; Nicolas Wentzensen
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

Review 2.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225

3.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.

Authors:  Maria Benevolo; Antonio Musio; Amina Vocaturo; Maria Gabriella Donà; Francesca Rollo; Irene Terrenato; Mariantonia Carosi; Edoardo Pescarmona; Giuseppe Vocaturo; Marcella Mottolese
Journal:  J Transl Med       Date:  2012-06-25       Impact factor: 5.531

Review 5.  New technologies for cervical cancer screening.

Authors:  Alaina J Brown; Cornelia L Trimble
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-11-25       Impact factor: 5.237

6.  Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein.

Authors:  Sean F Jabbar; Soyeong Park; Johannes Schweizer; Marthe Berard-Bergery; Henry C Pitot; Denis Lee; Paul F Lambert
Journal:  Cancer Res       Date:  2012-06-13       Impact factor: 12.701

Review 7.  Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Authors:  Patti E Gravitt; Jerome L Belinson; Jorge Salmeron; Keerti V Shah
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

8.  Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.

Authors:  Maria Benevolo; Amina Vocaturo; Donatella Caraceni; Deborah French; Sandra Rosini; Roberta Zappacosta; Irene Terrenato; Lucia Ciccocioppo; Antonio Frega; Paolo Giorgi Rossi
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

9.  E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population.

Authors:  Wen-Jing Shi; Hao Liu; Dan Wu; Zhen-Hua Tang; Yu-Chen Shen; Lin Guo
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

10.  HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.

Authors:  Patricia Luhn; Nicolas Wentzensen
Journal:  Curr Obstet Gynecol Rep       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.